This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Otezla
  • /
  • Study to Evaluate Safety and Effectiveness of Oral...
Clinical trial

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

Read time: 2 mins
Last updated:1st Sep 2010
Source: Clinical Trials
Identifier: NCT01194219
This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study was to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study was able to test for efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.
Category Value
Date last updated at source 2017-01-09
Study type(s) Interventional
Expected enrolment 844
Study start date 2010-09-01
Estimated primary completion date 2016-11-01

View full details